Table 4.

Multivariate analyses of TIM-3/PD-1/LAG-3+ iTILs among ER- breast cancer patients for BCSS.

Among ER- (# of events/n: 249/686)		Hazard Ratio for BCSS (95% CI)	P-value*
Age at diagnosis (Reference group:< 50)	≥ 50	0.89 (0.64–1.24)	0.49
Tumor grade (Reference group: grade 1–2)	Grade 3	2.22 (1.56–3.16)	< 0.001
Tumor size (Reference group: ≤ 2cm)	> 2	1.50 (1.14–1.98)	0.004
Lymphovascular invasion status (Reference group: negative)	Positive	1.355 (0.998–1.840)	0.052
Nodal status (Reference group: negative)	Positive	2.654 (1.887–3.731)	< 0.001
Adjuvant systemic therapy (Reference group: no AST)	TAM only Chemo only TAM+ chemo	0.851 (0.566–1.279) 0.739 (0.495–1.103) 1.193 (0.683–2.084)	0.436
TIM-3/PD-1/LAG-3+ iTILs (Reference group: TIM3-/PD1-/LAG3-)	TIM3-/PD1+/LAG3- TIM3-/PD1-/LAG3+ TIM3-/PD1+/LAG3+ TIM3+/PD1-/LAG3- TIM3+/PD1+/LAG3- TIM3+/PD1-/LAG3+ TIM3+/PD1+/LAG3+	0.499 (0.251–0.989) 0.498 (0.289–0.861) 0.586 (0.299–1.148) 0.615 (0.314–1.203) 0.348 (0.086–1.410) 0.959 (0.519–1.772) 0.165 (0.073–0.375)	0.046 0.012 0.119 0.155 0.139 0.893 < 0.001

*Wald-test